CompletedPhase 2NCT02739217
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
Studying Alström syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Liminal BioSciences Ltd.
- Principal Investigator
- Tarekegn Hiwot, MDThe Queen Elizabeth Hospital
- Intervention
- PBI-4050(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2016 – 2018
Study locations (1)
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02739217 on ClinicalTrials.govOther trials for Alström syndrome
Additional recruiting or active studies for the same condition.